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S U M M A R Y
The recent introduction of direct antiviral agents (DAAs) as a fundamental part of anti-hepatitis C virus
(HCV) therapy has dramatically improved the possibility of cure for patients with genotype 1, but at the
same time has increased the incidence of severe adverse events and the risk of reduced compliance. Here
we present the case of a 72-year-old Caucasian male suffering from a genotype 1b HCV infection, with a
previous history of virological breakthrough at the end of dual therapy with pegylated interferon and
ribavirin at standard dosages. The patient was retreated with telaprevir-based triple therapy, and despite
the early spontaneous interruption of treatment because of severe anemia and fatigue, he obtained a
sustained virological response. This case suggests that in selected genotype 1 HCV-infected patients,
primarily of subtype 1b, who require the interruption of anti-HCV therapy because of severe adverse
events or reduced compliance, a successful treatment can be obtained even with a very short course of
DAA-based triple therapy.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Hepatitis C virus (HCV) infection is a major health problem
worldwide, causing severe complications such as cirrhosis and its
sequelae, including end-stage liver disease and hepatocellular
carcinoma. Dual anti-HCV therapy with pegylated interferon
(PEG-IFN) and ribavirin (RBV) can improve liver histology and also
eradicate HCV. However, both of these objectives are more
difﬁcult to obtain for viral genotype 1 than for the other
genotypes. The recent introduction of direct antiviral agents
(DAAs) boceprevir (BOC) and telaprevir (TVR) into clinical practice
has substantially improved the therapeutic outlook for patients
with genotype 1 HCV infections; indeed, sustained virological
response (SVR) rates have increased from approximately 35–50%
for dual therapy to 63–75% for DAA-based triple therapy in
treatment-naı¨ve subjects and to 69–83% in relapsers; they are
now satisfactory even in previous non-responders. Moreover, the§§ Presented in part at the 11th National Congress of the Italian Society of
Infectious and Tropical Diseases (‘‘118 Congresso Nazionale SIMIT’’), Chieti-Pescara,
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http://dx.doi.org/10.1016/j.ijid.2013.09.002use of DAAs may also allow a shortened duration of therapy,
except in non-responder and cirrhotic patients, by virtue of a
response-guided therapeutic strategy. This results in simpliﬁca-
tion of therapy, higher compliance, and a lower global cost of
treatment.1
However, subjects on either BOC- or TVR-based treatment
develop signiﬁcantly more adverse events than do those on dual
therapy, and this can complicate treatment and sometimes lead to
its discontinuation. In particular, patients with more advanced
disease develop an increased incidence of moderate and also
severe anemia, which have been found to be higher in the post-
marketing surveillance than in the registered trials.2 Here we
report the case of a treatment-experienced patient who was
retreated with TVR-based triple therapy and who developed a
severe anemia that induced him to interrupt all anti-HCV drugs
early, but who obtained an SVR all the same.
2. Case report
In 2007, a 67-year-old Caucasian male with a medical history of
absolute polycythemia, arterial hypertension, and metabolic
syndrome, without other signiﬁcant factors such as alcohol abuse
or viral co-infections, suffered from an acute subtype 1b HCV
infection, probably acquired in the hospital environment following
either endoscopic retrograde cholangiopancreatography or subse-ciety for Infectious Diseases. Open access under CC BY license.
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infection, remaining positive at 12 weeks after initial presenta-
tion. As a result he was treated with subcutaneous PEG-IFN alpha-
2a plus oral RBV at standard dosages. Despite a rapid virological
response (RVR), viral breakthrough occurred at the end of
24-week therapy; the patient was followed-up regularly in the
subsequent years. In November 2011, a liver biopsy showing
moderate necroinﬂammatory activity and severe ﬁbrosis (Meta-
vir A2/F3) and an unfavorable genotype in the IL28b genetic test
(rs12979860 T/T) provided an indication for triple anti-HCV
therapy. In April 2012, the patient (now aged 72 years, weight
80 kg, body mass index 26.73 kg/m2) initiated subcutaneous PEG-
IFN alpha-2b 120 mg/week, oral RBV 1200 mg/day, and oral TVR
2250 mg/day, in accordance with Named Patient Program use.
Major baseline values were the following: HCV-RNA >7 log10
copies/ml, alanine transaminase (ALT) 73 IU/ml, and hemoglobin
(Hb) 17.3 g/dl. At week 2, HCV-RNA was undetectable, ALT was 23
IU/ml, and Hb was 15.5 g/dl. Subsequently, the patient developed
progressive fatigue, with Hb declining to 10.8 g/dl at week 4 and to
9.3 g/dl at week 5; in the meanwhile, the RBV dose was ﬁrst
reduced to 1000 mg/day and then subcutaneous erythropoietin
alpha 40 000 units/week was started. At week 6, the patient was
admitted to the hospital for worsening of both fatigue and anemia
(Hb 7.9 g/dl), which required a red blood cell transfusion. At the
beginning of week 7, he spontaneously suspended all anti-HCV
drugs. During the following 4 weeks, Hb steadily rose to the
normal range, and the fatigue progressively diminished and then
subsided. HCV-RNA remained persistently undetectable through-
out controls at 1, 3, 6, 9, and 12 months after discontinuation of
anti-HCV therapy.
3. Discussion
Combination therapy with PEG-IFN and RBV produces an SVR
in no more than 50% of genotype 1 HCV-infected patients,
compared to 70–80% of patients infected with genotypes 2 and
3.1 This and other limitations of dual anti-HCV therapy, such as
the long treatment duration (48–72 weeks) and the many side
effects of both PEG-IFN and RBV, have resulted in the develop-
ment of some new promising molecules named DAAs. The ﬁrst –
BOC and TVR – have just been introduced into clinical practice as
part of triple anti-HCV therapy in combination with PEG-IFN and
RBV.
Potential toxicity is one of the most important limitations of
DAAs, in particular the risk of precipitating anemia that is
caused by RBV, although by a different pathogenic mechanism.
In registered trials, anemia occurred in approximately a third
of patients treated with TVR-based triple therapy, whereas this
ﬁgure has been found to be even higher in post-marketing
surveillance studies, in particular in subjects with advanced
ﬁbrosis/cirrhosis. In one of these recent studies, independent
predictors of severe anemia were primarily a baseline Hb level
13 g/dl, and secondarily, age 65 years, female gender, and
no lead-in phase.2 Our male patient started from a pretreat-
ment Hb level that was very high (17.3 g/dl) being known as
polycythemic, but he is elderly and did not undergo a lead-in
phase. We believe that these latter negative factors do not
explain per se why the patient suffered from a worsening
fatigue with difﬁculty in all normal daily activities, such that
he spontaneously decided to interrupt all anti-HCV drugs.
Therefore, accurate monitoring of the Hb level throughout the
entire duration of treatment, along with its early management,
is of crucial importance in order to both maintain the maximal
drug dosages and to limit the risk of therapy discontinuation
due to toxicity. In light of this and other objectives (i.e.,
preventing drug–drug interactions and investigating patientadherence), a potential role for therapeutic drug monitoring
could be assumed in the future in the ﬁeld of triple anti-HCV
treatment, as it is now for other anti-infective therapies
(antibacterial, antifungal).3
Our patient presented with several baseline factors associated
with a poor rate of SVR, i.e., advanced age, severe ﬁbrosis,
metabolic syndrome, high HCV-RNA, and IL28b T/T genotype;
however he obtained a RVR as early as week 2, probably favored by
the rapid decline in HCV-RNA that it is well known to occur during
the ﬁrst 2 weeks of TVR therapy.4 The severe anemia caused by
concomitant RBV and TVR induced the patient to interrupt
treatment after 6 weeks, however the possibility of obtaining an
SVR was not impaired. To our knowledge, such a short duration of
anti-HCV therapy has so far been evaluated only in treatment-
naı¨ve genotype 1 patients with the favorable IL28B C/C polymor-
phism (rs12979860). These subjects, treated with a 6-week
quadruple regimen containing two novel DAAs (GS-5885 and
GS-9451) plus PEG-IFN and RBV, showed an SVR rate as high as 79%
– although lower than in the 12-week arm (98%) – in particular in
patients with a high baseline viral load and body mass index. Of
note, fewer dose reductions and therapy discontinuations were
observed in the 6-week arm.5
Well-designed studies including a rigorous selection of
patients with their risk factors and a clear deﬁnition of treatment
schedules and primary and secondary endpoints are required in
order to draw ﬁrm conclusions, however the case we have
reported here offers – in our opinion – some interesting starting
points for future research. First, if TVR-based anti-HCV therapy
needs to be stopped because of toxicity or reduced compliance, an
SVR can still be obtained with as short as 6–8 weeks of treatment
in selected genotype 1 HCV-infected subjects. Second, some
characteristics carried by our patient (subtype 1b, absence of
cirrhosis and viral co-infections, achievement of a RVR), along
with other favorable factors (no previous anti-HCV therapy, IL28b
C/C polymorphism, low baseline HCV-RNA) can identify those
subjects who are candidates for a shorter anti-HCV treatment
duration and, therefore, for a reduced exposure to potentially
severe adverse events.
Conﬂict of interest: All authors who took part in this study
declare that they have no ﬁnancial or personal relationships with
other people or organizations that could inappropriately have
inﬂuenced (biased) their work.
Funding source: All authors who took part in this study declare
that no sponsors had any role in the study design, in the collection,
analysis, and interpretation of data, in the writing of the
manuscript, or in the decision to submit the manuscript for
publication.
Ethical approval: All authors who took part in this study declare
that no ethical approval was required because personal patient
details are not included in any part of the paper.
References
1. Farnik H, Zeuzem S. New antiviral therapies in the management of HCV infection.
Antivir Ther 2012;17:771–83.
2. He´zode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy
in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of
the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. J
Hepatol 2013;59:434–41.
3. Dolton MJ, Ray JE, McLachlan AJ. Telaprevir and boceprevir: a potential role for
therapeutic drug monitoring. Ther Drug Monit 2013;35:414–5.
4. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de
Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-
950: a phase 1b, placebo-controlled, randomized study. Gastroenterology
2006;131:997–1002.
5. Thompson A, Han S, Shiffman ML, Rossaro L, Ghalib R, Beavers K, et al. GS-5885
plus GS-9451 plus peginterferon and ribavirin (PR) for six or twelve weeks
achieves high SVR12 rates in treatment-naı¨ve genotype 1 IL28B CC patients. J
Hepatol 2013;58:S29.
